NCBiotech News

Four North Carolina universities have teamed up to win a $5.7 million federal grant for diabetes research.

CED's Venture Connect Online starts today and runs for the next three weeks, giving over 90 growth-stage companies exposure to potential investors from around the world.

People who have recovered from COVID-19 may donate potentially lifesaving plasma at UNC, and Grifols is also collecting it at plasma donor sites elsewhere around the country.

Banner Life Sciences, a High Point pharmaceutical company, has gained final regulatory approval of a drug for treating multiple sclerosis.

Durham-based Chimerix is another step closer to getting the final go-ahead for its novel smallpox treatment.

First Flight Venture Center has named Krista Covey as the incubator’s new president, effective May 18. 

For those feeling the health and economic heat from COVID-19 – and that’s just about everyone – Heat Biologics says it could soon offer up a potential solution.

Duke University biomedical engineers are using an NSF grant to convert a rapid testing platform originally designed to detect Ebola to catch antigens to COVID-19.

RedHill Biopharma, an Israeli specialty company with U.S. headquarters in Raleigh, says all six COVID-19 patients who recently received its investigative drug, opaganib, got better. 

Wake Forest University researchers have a $3 million NSF grant to study why tomato plants won’t bear fruit when things get hot.

Morrisville precision health company Metabolon is working with a Seattle non-profit to study variations in COVID-19 outcomes and target potential therapies to deal with those variations.

AskBio has acquired BrainVectis, a French company that is developing a potential gene therapy for Huntington’s disease, a fatal genetic disease of the brain.

Healthcare workers and first responders who have symptoms of COVID-19 now can use a LabCorp kit to self-test for the coronavirus at home.

Panaceutics Nutrition, a provider of personalized nutrition products with operations in Research Triangle Park, has closed the first tranche of a committed funding round of over $5 million.

RedHill Biopharma is another step closer to getting one of its potential treatments for COVID-19 tested.